Hack Andrew A. F.

CIK 00016574347 companiesCAMBRIDGE, MA

SEC Profile

Transactions

Companies

Filings

CIK

0001657434

Recent Transactions

50 trades

Sale
Nuvalent, Inc.$NUVL
Class A Common Stock
2024-12-11$88.00/sh−1,250,000→ 1,447,267 total
Award
Nuvalent, Inc.$NUVL
Class A Common Stock
2024-06-12+2,499→ 2,499 total
Award
Nuvalent, Inc.$NUVL
Stock Option (right to buy)
2024-06-12+3,789→ 3,789 total
Award
Mersana Therapeutics, Inc.$MRSN
Stock Option (right to buy)
2024-06-11+55,000→ 55,000 total
Sale
Nuvalent, Inc.$NUVL
Class A Common Stock
2024-03-27$72.31/sh−791,795→ 2,697,267 total
Sale
Nuvalent, Inc.$NUVL
Class A Common Stock
2024-03-27$76.88/sh−88,205→ 3,489,062 total
Sale
DYNAVAX TECHNOLOGIES CORP$DVAX
Common Stock
2023-08-08$14.39/sh−1,500,000→ 915,000 total
Award
Nuvalent, Inc.$NUVL
Stock Option (Right to Buy)
2023-06-15+15,000→ 15,000 total
Sale
DYNAVAX TECHNOLOGIES CORP$DVAX
Common Stock
2023-06-14$12.68/sh−500,000→ 2,415,000 total
Award
Mersana Therapeutics, Inc.$MRSN
Stock Option (right to buy)
2023-06-08+18,355→ 18,355 total
Award
Mersana Therapeutics, Inc.$MRSN
Common Stock
2023-06-08+14,467→ 14,467 total
Award
DYNAVAX TECHNOLOGIES CORP$DVAX
Stock Option (Right to Buy)
2023-05-26+22,500→ 22,500 total
Award
DYNAVAX TECHNOLOGIES CORP$DVAX
Common Stock
2023-05-26+5,357→ 10,714 total
Sale
DYNAVAX TECHNOLOGIES CORP$DVAX
Common Stock
2023-05-18$10.55/sh−1,000,000→ 2,915,000 total
Sale
DYNAVAX TECHNOLOGIES CORP$DVAX
Common Stock
2022-12-06$11.60/sh−1,500,000→ 3,915,000 total
Purchase
Nuvalent, Inc.$NUVL
Class A Common Stock
2022-11-03$33.50/sh+149,253→ 3,577,267 total
Sale
DYNAVAX TECHNOLOGIES CORP$DVAX
Common Stock
2022-08-15$14.68/sh−3,000,000→ 5,415,000 total
Award
Nuvalent, Inc.$NUVL
Stock Option (Right to Buy)
2022-06-16+20,000→ 20,000 total
Award
Mersana Therapeutics, Inc.$MRSN
Stock Option (right to buy)
2022-06-09+45,000→ 45,000 total
Purchase
Mersana Therapeutics, Inc.$MRSN
Common Stock
2022-06-02$3.20/sh+14,760→ 8,663,673 total
Purchase
Mersana Therapeutics, Inc.$MRSN
Common Stock
2022-05-31$3.28/sh+80,759→ 8,648,913 total
Purchase
Mersana Therapeutics, Inc.$MRSN
Common Stock
2022-05-26$3.19/sh+75,000→ 8,568,154 total
Award
DYNAVAX TECHNOLOGIES CORP$DVAX
Restricted Stock Unit
2022-05-26+5,357→ 5,357 total
Award
DYNAVAX TECHNOLOGIES CORP$DVAX
Option (Right to Buy)
2022-05-26+22,500→ 22,500 total
Purchase
Mersana Therapeutics, Inc.$MRSN
Common Stock
2022-05-25$3.17/sh+90,155→ 8,493,154 total
Purchase
Mersana Therapeutics, Inc.$MRSN
Common Stock
2022-05-24$3.29/sh+100,000→ 8,402,999 total
Purchase
Mersana Therapeutics, Inc.$MRSN
Common Stock
2022-05-23$3.35/sh+15,599→ 8,302,999 total
Purchase
Mersana Therapeutics, Inc.$MRSN
Common Stock
2022-05-20$3.46/sh+100,000→ 8,287,400 total
Purchase
Mersana Therapeutics, Inc.$MRSN
Common Stock
2022-05-19$3.49/sh+100,000→ 8,187,400 total
Purchase
Mersana Therapeutics, Inc.$MRSN
Common Stock
2022-05-18$3.35/sh+211,268→ 8,087,400 total
Purchase
Mersana Therapeutics, Inc.$MRSN
Common Stock
2022-05-17$3.18/sh+3,440→ 7,876,132 total
Purchase
Mersana Therapeutics, Inc.$MRSN
Common Stock
2022-05-16$3.10/sh+135,292→ 7,872,692 total
Purchase
Mersana Therapeutics, Inc.$MRSN
Common Stock
2022-04-13$4.05/sh+617,284→ 7,737,400 total
Purchase
Mersana Therapeutics, Inc.$MRSN
Common Stock
2022-04-12$4.18/sh+598,086→ 7,120,116 total
Purchase
Mersana Therapeutics, Inc.$MRSN
Common Stock
2022-02-07$4.42/sh+1,136,363→ 6,522,030 total
Award
Mersana Therapeutics, Inc.$MRSN
Stock Option (Right to Buy)
2022-01-03+10,995→ 10,995 total
Purchase
Mersana Therapeutics, Inc.$MRSN
Common Stock
2021-12-30$6.15/sh+815,000→ 5,385,667 total
Purchase
Mersana Therapeutics, Inc.$MRSN
Common Stock
2021-12-29$5.75/sh+875,000→ 4,570,667 total
Conversion
DYNAVAX TECHNOLOGIES CORP$DVAX
Series B Convertible Preferred Stock
2021-08-27−1,891→ 0 total
Sale
DYNAVAX TECHNOLOGIES CORP$DVAX
Common Stock
2021-08-27$16.22/sh−2,000,000→ 8,415,000 total
Conversion
DYNAVAX TECHNOLOGIES CORP$DVAX
Common Stock
2021-08-27+1,891,000→ 10,415,000 total
Sale
DYNAVAX TECHNOLOGIES CORP$DVAX
Common Stock
2021-08-09$10.80/sh−2,250,000→ 8,524,000 total
Conversion
DYNAVAX TECHNOLOGIES CORP$DVAX
Series B Convertible Preferred Stock
2021-08-09−2,249→ 1,891 total
Conversion
DYNAVAX TECHNOLOGIES CORP$DVAX
Common Stock
2021-08-09+2,249,000→ 10,774,000 total
Conversion
Nuvalent, Inc.$NUVL
Class A Common Stock
2021-08-02+2,693,014→ 2,693,014 total
Purchase
Nuvalent, Inc.$NUVL
Class A Common Stock
2021-08-02$17.00/sh+735,000→ 3,428,014 total
Conversion
Nuvalent, Inc.$NUVL
Series B Preferred Stock
2021-08-02−14,494,154→ 0 total
Award
Nuvalent, Inc.$NUVL
Stock Option (Right to Buy)
2021-07-28+43,000→ 43,000 total
Award
Mersana Therapeutics, Inc.$MRSN
Stock Option (right to buy)
2021-06-11+25,050→ 25,050 total
Sale
DYNAVAX TECHNOLOGIES CORP$DVAX
Warrants (Right to Buy)
2021-06-10−2,916,250→ 0 total

Companies

Recent Filings

Address

C/O EDITAS MEDICINE, INC. 11 HURLEY ST.

CAMBRIDGE, MA, 02141

View on SEC.gov